ARCHIVES

Zaltrap Economics 101: The Pricing And Repricing of an Expensive Drug

This article is from The Cancer Letter archive.

Vol. 38 No. 43 | November 16, 2012

Download PDF Visit The Full Archive

Related Articles

NCI Study Says 2 Million US Women Could Benefit from Tamoxifen

April 11, 2003

NIH Funding Strategies, UICC Fellowships

December 4, 1992

NCI Moves Ahead To Find “Less-Hazardous” Cigarette

April 19, 1974

Study: Oncotype DX Score Can Predict Local Recurrence

March 29, 2013

NCCS Changes Web Domain; NCCN Plans Clinical Trials Network

June 7, 2002

Report Finds NIH Not At Fault in Case Of P-32 Ingestion

September 26, 1997